Skip to main content
Erschienen in: Reproductive Biology and Endocrinology 1/2013

Open Access 01.12.2013 | Research

Functional proteomic analysis of seminal plasma proteins in men with various semen parameters

Erschienen in: Reproductive Biology and Endocrinology | Ausgabe 1/2013

Abstract

Background

Alterations at the molecular level in spermatozoa and seminal plasma can affect male fertility. The objective of this study was to determine if analysis of differential expression of proteins in varying semen parameters can serve as potential biomarkers for male infertility.

Methods

The differential expression of proteins in the seminal plasma of men based on sperm count and morphology were examined utilizing proteomic tools. Subjects were categorized based on sperm concentration and morphology into 4 groups: 1) normal sperm count and normal morphology (NN); 2) normal sperm count and abnormal morphology (NA); 3) oligozoospermia and normal morphology (ON); and 4) oligozoospermia and abnormal morphology (OA). Proteomic analysis was performed by LC-MS/MS followed by functional bioinformatics analysis. Protein distribution in the NA, ON and OA groups was compared with that of the NN group.

Results

Twenty proteins were differentially expressed among the 4 groups. Among the unique proteins identified, 3 were downregulated in the NA group, 1 in the ON group and 1 in the OA group while 2 were upregulated in the ON and OA groups. The functional analysis 1) identified biological regulation as the major processes affected and 2) determined that most of the identified proteins were of extracellular origin.

Conclusions

We have identified proteins that are over-or underexpressed in the seminal plasma of men with poor sperm quality. The distinct presence of some of the proteins may serve as potential biomarkers and provide insight into the mechanistic role played by these proteins in male infertility. Further studies using Western Blot analysis are required to validate these findings.
Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1477-7827-11-38) contains supplementary material, which is available to authorized users.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

RS participated in the study conception/design, review of the data and writing of the manuscript and final approval. BW, SY and BG contributed to data interpretation and participated in the paper redaction; GM participated in the review of the data and writing of the manuscript. AA contributed to the study design, and review of the data. RJ participated in organizing the subject information and review of the study findings. ES provided the subjects and participated in the study design. All authors read and approved the final manuscript.

Background

Infertility is a major problem in 15% of couples worldwide. Male factors may play a role in half of these cases [1]. Most causes of male infertility are idiopathic. Semen analysis remains the cornerstone in the evaluation of male infertility. However, the data generated from this routine testing do not provide any insight into the underlying problems associated with developing spermatozoa. Sperm morphology plays an important role in conception, and both fertilization and pregnancy rates are affected when morphologically normal sperms are below 5%. It is also a reflection of poor testicular physiology and is an important factor in male infertility [24]. However, a significant overlap of semen parameters such as sperm count, motility and morphology have been documented [5]. Idiopathic and unexplained infertility cannot be diagnosed by routine sperm function tests [6]. Similarly, oligozoospermic men may have other underlying pathologies that may contribute to infertility. Evaluation solely based on semen analysis is insufficient to determine the fertility status of the male partner.
Spermatogenesis is a complex process that involves development of the undifferentiated germ cells into a highly specialized spermatozoon capable of fertilizing an oocyte [7]. Fertilization requires physical proximity of the spermatozoa and the oocytes. Seminal plasma composed of secretions from the testis, epididymis and male accessory glands [8] provides a favorable environment and serves as a vehicle for the spermatozoa as it travels to meet the oocyte.
Seminal plasma contains unique proteins necessary for sperm function and survival [9, 10]. Seminal plasma proteins play a variety of roles—they help protect the sperm by binding to the sperm surface during ejaculation and play a key role in capacitation, acrosome reaction, and sperm-egg fusion [11, 12]. They can also modulate immune response in male and female reproductive tracts, ensuring that the most competent spermatozoa meet the oocyte during fertilization [13]. Thus, seminal plasma proteins can serve as important biomarkers for male infertility [14].
Conventional 1-Dimensional gel electrophoresis studies have provided information in relation to sperm proteins and their function in normal and abnormal spermatozoa [15, 16]. Advancements in mass- spectrometry and proteomic-based techniques have made it possible to analyze the complex protein mixtures found in tissues and body fluids. Several attempts have been made to identify these proteins using high-throughput techniques such as matrix assisted laser desorption ionization – time of flight (MALDI-TOF) mass spectrometry (MS) and liquid chromatography – tandem mass spectrometry (LC-MS/MS) and linear ion trap (LTQ-Orbitrap) mass spectrometry [1721].
Alterations at the molecular level in spermatozoa and the seminal plasma may contribute to male infertility. However, even after accounting for all the advances in proteomics, there has been a great lack of detailed data in the area of comparative analysis of seminal plasma proteins associated with male infertility.
The objective of the present study was 1) to compare the differential expression of proteins in the seminal plasma from subjects with normal or abnormal sperm concentration and sperm morphology utilizing proteomic tools such as LC-MS/MS and 2) utilize the functional bioinformatics analysis to identify the cellular origin and the differentially affected processes and/or pathways of these proteins to gain insights into the mechanistic roles played by these proteins in effecting the observed phenotypes. These analyses could possibly identify potential biomarkers for male infertility.

Methods

After obtaining Institutional Review Board approval, written consent was obtained from all subjects. Semen samples were obtained from 64 subjects who were healthy male volunteers of unproven fertility (n = 21) and men presenting to our infertility clinic for evaluation (n = 43). Semen samples were collected by masturbation after 2–3 days of sexual abstinence. Samples with leukocytospermia--a high concentration of white blood cells (>1 × 106 WBC/mL)--were examined for the presence of granulocytes by the peroxidase or the Endtz test. The patients with a positive Endtz test were excluded from the study. Semen analysis was conducted according to WHO criteria as described below [22].

Semen analysis

Following complete liquefaction (average time: 20 minutes and no more than 60 min.), manual semen analysis was performed using a MicroCell counting chamber (Vitrolife, San Diego, CA) to determine sperm concentration and percentage motility according to WHO guidelines [22]. Viability was determined with Eosin - Nigrosin stain. Smears of the raw semen were stained with a Diff-Quik kit (Baxter Healthcare Corporation, Inc., McGaw Park, IL) for assessment of sperm morphology according to WHO criteria [22].
After analysis of semen parameters, aliquots of the samples were frozen at −80°C for proteomic analysis.

Preparation of samples for proteomic analysis

Samples were divided into 4 groups based only on normal sperm concentration and normal morphology parameters according to WHO criteria [22]. The groups were as follows: Group 1: normal sperm count and normal morphology (NN = 26); Group 2: normal sperm count and abnormal morphology (NA = 22); Group 3: oligozoospermia and normal morphology (ON = 6) and group 4: oligozoospermia and abnormal morphology (OA = 10).
To prepare the samples for proteomic analysis, they were thawed, and clear seminal plasma was separated from the sperm pellet by centrifugation at 3,000 g for 30 minutes to ensure complete removal of the cellular components. Seminal plasma samples were pooled into replicates (NN = 5; NA = 4; ON = 1; OA = 2). Each sample was dissolved in 98% acetonitrile containing 0.1% trifluoroacetic acid followed by lyophilization at −80°C under vacuum for 2 days. The lyophilized sample was used to estimate the protein content. The samples were first precipitated in cold acetone and centrifuged at 10,000 g for 15 minutes. The acetone was poured off, and the protein pellet was allowed to dry at room temperature. The protein pellet was solubilized in a buffer of 6 M urea, 100 mM Tris, pH 8.0. The proteins were then reduced by the addition of DTT (200 mM in 100 mM Tris) for 15 minutes at room temperature and then alkylated by the addition of 200 mM iodoacetamide (200 mM in 100 mM Tris) for 20 minutes at room temperature. The urea concentration was then reduced to approximately 1.2 M, and trypsin was added at a ratio of 1:50. Digestion was carried out overnight at room temperature. The digestion was stopped the next morning by adding acetic acid to lower the pH to <6, and the samples were centrifuged to remove insoluble material. The digests were then prepared for LC-MS/MS analysis by using PepClean C-18 spin columns to desalt the samples, which were then brought up in 50 μL of 1% acetic acid.

Liquid chromatography – mass spectrometer analysis (LC-MS/MS)

The LC-MS system is a Finnigan LTQ linear ion trap mass spectrometer system. The high performance liquid chromatography (HPLC) column was a self-packed 9 cm × 75 μm (internal diameter) Phenomenex Jupiter C18 reversed-phase capillary chromatography column. Ten μL volumes of the extract were injected, and the peptides that were eluted from the column by an acetonitrile/0.1% formic acid gradient at a flow rate of 0.25 μL/min were introduced into the source of the mass spectrometer on-line. The microelectrospray ion source was set at 2.5 kV. The digest was analyzed using the data-dependent multitask capability of the instrument acquiring full scan mass spectra to determine peptide molecular weights and product ion spectra to determine the amino acid sequence in successive instrument scans [23]. This mode of analysis produces approximately 2500 collision-induced dissociation (CID) spectra of ions ranging in abundance over several orders of magnitude. The spectral count (SC) for each protein was determined. Normalized spectral count (NSC) was obtained by dividing the spectral count for each protein and the total number of spectral counts identified in the sample. The spectral counts were quantitated by taking the normalized spectral count ratio for two sets of samples. A protein was considered to be differentially expressed if there was at least a two-fold difference in the spectral count ratios between the two samples.

Data analysis

All CID spectra collected in the experiment were used to search the National Center for Biotechnology Information (NCBI) human reference sequence database with the search engine MASCOT (Matrix Science, Boston, MA, http://​www.​matrixscience.​com). After identification, a database consisting of all proteins identified in these searches was created and used for a second set of searches. These searches were performed with a program called SEQUEST, and the results from these SEQUEST searches were used to determine the spectral counts. Furthermore, functional bioinformatics analysis was done using publicly available software packages such as Gene Ontology annotations from GO Term Finder [24] and GO Term Mapper [25], UniProt [26], STRAP [27], and BioGPS [28]) as well as proprietary software packages (Ingenuity Pathway Analysis (IPA) from Ingenuity® Systems [29], and Metacore™ from GeneGo Inc. [30]) to identify the differentially affected processes, pathways, interactions, and cellular distribution of the proteins in the four study groups.

Results

Analysis of the proteins identified by LC-MS/MS

The proteins identified in the 12 replicates from NN, NA, ON and OA group showing protein name, NCBI database index, molecular weight, peptide coverage and Mascot score is shown in Table 1. A protein was considered significant if the SC cut off value was ≥ 10 in at least one sample and present in at least 50% of the samples in a group. They were considered ‘low abundant’ if the SC cut-off value was ≤10 in all the samples. The differentially expressed proteins (DEP) in the NA, OA, and ON groups were categorized based on the NSC ratio cut-off values of > 2 (for over-expressed) or < 0.5 (for under-expressed) in comparison to the NN group. We identified a total of 35 proteins; of these, 10 were classified as low abundant. Amongst the remaining 25 significantly abundant proteins (24 in NN, 23 in NA, 20 in OA, and 16 in ON), 11 were present in all the samples, and 13 proteins were identified as unique to one or two or three of the four samples. 20 proteins were identified as differentially expressed in the NA, OA, and ON groups as compared to NN group, with 2 proteins differentially expressed in all three groups (Figure 1). The remaining 18 were present in either of the groups (Figure 2). A detailed list of the proteins classified under these categories (Common, Unique, Significant, Low Abundant, and Differentially Expressed) is shown in Table 2.
Table 1
Identification of proteins in the 12 replicates from NN, NA, ON and OA group showing protein name, NCBI database index, molecular weight, peptide coverage and Mascot score
Identification
LTQ
No. Protein name
NCBI database index number
Calculated MW in kDa
PI
Peptides (%coverage)
Mascot score
Sample NN1
semenogelin II precursor
4506885
65
9
8(10%)
9536
prolactin induced protein
4505821
16
8.2
3(20%)
5335
albumin preproprotein
4502027
71
5.9
9(22%)
4805
epididymal secretory protein E1 precursor
5453678
16
7.5
3 (21%)
794
prosaposin isoform a preproprotein
11386147
59
5
1 (2%)
658
mucin 6, gastric
151301154
263
7.2
4 (3%)
461
prostate specific antigen isoform 4 preproprotein
71834855
24
7
3 (15%)
460
armadillo repeat protein
4502247
105
6.3
3(5%)
413
cathepsin D preproprotein
4503143
45
6.1
1 (4%)
285
zinc alpha-2-glycoprotein 1
4502337
34
5.7
2 (12%)
260
cystatin S precursor
4503109
16
4.9
2 (31%)
178
ubiquitin and ribosomal protein S27a precursor
4506713
18
9.6
1 (10%)
173
clusterin isoform 1
42716297
58
6.2
3 (10%)
142
Sample NN2
prolactin-induced protein
4505821
16
8.2
10 (69%)
32886
semenogelin II precursor
4506885
65
9
17 (33%)
22468
semenogelin I isoform b preproprotein
38049014
45
9.2
13 (33%)
5388
albumin preproprotein
4502027
71
5.9
24 (54%)
15508
prostate specific antigen isoform 1 preproprotein
4502173
29
7.6
11 (61%)
5087
lactotransferrin precursor
54607120
80
8.5
22 (42%)
4281
zinc alpha-2-glycoprotein 1
4502337
34
5.7
11 (44%)
3424
cystatin S precursor
4503109
16
4.9
5 (44%)
1809
prosaposin isoform a preproprotein
11386147
59
5
9 (33%)
880
epididymal secretory protein E1 precursor
5453678
16
7.5
4 (52%)
786
serine proteinase inhibitor, clade A, member 1
50363217
46
5.3
11 (48%)
737
mucin 6, gastric
151301154
263
7.2
11 (9%)
524
extracellular matrix protein 1 isoform 1 precursor
221316614
62
6.2
7 (31%)
504
cystatin C precursor
4503107
16
9
6 (68%)
432
tissue inhibitor of metalloproteinase 1 precursor
4507509
23
8.4
4 (40%)
411
fibronectin 1 isoform 3 preproprotein
16933542
262
5.4
8(11%)
353
cathepsin D preproprotein
4503143
45
6.1
3 (11%)
266
acid phosphatase, prostate short isoform precursor
6382064
44
5.8
2 (12%)
166
carboxypeptidase E preproprotein
4503009
53
5
5 (20%)
153
clusterin isoform 1
42716297
58
6.2
2 (7%)
106
Sample NN3
prolactin-induced protein
4505821
16
8.2
10 (66%)
24697
semenogelin II precursor
4506885
65
9
19 (35%)
13533
semenogelin I isoform b preproprotein
38049014
45
9.2
15 (39%)
2633
albumin preproprotein
4502027
71
5.9
30 (60%)
8842
prostate specific antigen isoform 1 preproprotein
4502173
29
7.6
16 (70%)
8634
lactotransferrin precursor
54607120
80
8.5
23 (49%)
4607
zinc alpha-2-glycoprotein 1
4502337
34
5.7
9 (42%)
3935
epididymal secretory protein E1 precursor
5453678
16
7.5
6 (52%)
1214
tissue inhibitor of metalloproteinase 1 precursor
4507509
23
8.4
3 (29%)
987
prosaposin isoform a preproprotein
11386147
59
5
5 (21%)
833
extracellular matrix protein 1 isoform 1 precursor
221316614
62
6.2
6 (22%)
766
cystatin S precursor
4503109
16
4.9
5 (49%)
621
beta 2 microglobulin precursor
4757826
13
6
2 (21%)
523
fibronectin 1 isoform 3 preproprotein
16933542
262
5.4
4 (2%)
410
orosomucoid 1 precursor
167857790
23
5
3 (16%)
397
cystatin C precursor
4503107
16
9
3 (26%)
301
mucin 6, gastric
151301154
263
7.2
7 (7%)
288
cathepsin D preproprotein
4503143
45
6.1
2 (11%)
228
carboxypeptidase E preproprotein
4503009
53
5
3 (16%)
193
acidic epididymal glycoprotein-like 1 isoform 1 precursor
25121982
29
5.5
2 (10%)
166
galectin 3 binding protein
5031863
66
5.1
4 (11%)
165
clusterin isoform 1
42716297
58
6.2
2 (7%)
158
acid phosphatase, prostate short isoform precursor
6382064
44
5.8
5 (16%)
128
prostaglandin (H2) D-isomerase −1 peptide
32171249
21
7.6
1 (8%)
115
Sample NN4
prolactin-induced protein
4505821
16
8.2
12 (76%)
36052
semenogelin II precursor
4506885
65
9
16 (32%)
17746
semenogelin I isoform b preproprotein
38049014
45
9.2
14 (34%)
2723
lactotransferrin precursor
54607120
80
8.5
39 (61%)
8695
albumin preproprotein
4502027
71
5.9
23 (48%)
8361
prostate specific antigen isoform 1 preproprotein
4502173
29
7.6
15 (67%)
7417
zinc alpha-2-glycoprotein 1
4502337
34
5.7
11 (38%)
3979
mucin 6, gastric
151301154
263
7.2
14 (12%)
1685
epididymal secretory protein E1 precursor
5453678
16
7.5
7 (70%)
1428
acid phosphatase, prostate short isoform precursor
6382064
44
5.8
9 (26%)
1384
clusterin isoform 1
42716297
58
6.2
6 (16%)
1148
orosomucoid 1 precursor
167857790
23
5
4 (32%)
942
orosomucoid 2
4505529
23
5
2 (12%)
207
prosaposin isoform a preproprotein
11386147
59
5
6 (27%)
941
extracellular matrix protein 1 isoform 1 precursor
221316614
62
6.2
7 (25%)
731
tissue inhibitor of metalloproteinase 1 precursor
4507509
23
8.4
3 (29%)
635
beta 2 microglobulin precursor
4757826
13
6
2 (21%)
489
fibronectin 1 isoform 3 preproprotein
16933542
262
5.4
4 (3%)
447
cystatin C precursor
4503107
16
9
3 (26%)
391
carboxypeptidase E preproprotein
4503009
53
5
4 (14%)
358
galectin 3 binding protein
5031863
66
5.1
5 (14%)
341
transferrin
4557871
79
6.8
2 (4%)
275
acidic epididymal glycoprotein-like 1 isoform 1 precursor
25121982
29
5.5
2 (10%)
238
cystatin S precursor
4503109
16
4.9
2 (20%)
205
serine proteinase inhibitor, clade A, member 1
50363217
46
5.3
3 (12%)
187
cathepsin D preproprotein
4503143
45
6.1
2 (11%)
185
prostaglandin (H2) D-isomerase −1 peptide
32171249
21
7.6
1 (8%)
133
Sample NN5
prolactin-induced protein
4505821
16
8.2
8 (44%)
15001
semenogelin II precursor
4506885
65
9
10 (14%)
7235
albumin preproprotein
4502027
71
5.9
17 (39%)
2621
epididymal secretory protein E1 precursor
5453678
16
7.5
3 (23%)
552
prostate specific antigen isoform 1 preproprotein
4502173
29
7.6
5 (22%)
539
cystatin S precursor
4503109
16
4.9
2 (23%)
332
zinc alpha-2-glycoprotein 1
4502337
34
5.7
4 (19%)
250
prosaposin isoform a preproprotein
11386147
59
5
1 (2%)
239
prostatic acid phosphatase precursor
6382064
44
5.8
2 (4%)
180
lactotransferrin
54607120
80
8.5
4 (10%)
173
clusterin isoform 1
42716297
58
6.2
2 (7%)
157
galectin 3 binding protein
5031863
66
5.1
2 (4%)
152
extracellular matrix protein 1 isoform 1 precursor
4758236
62
6.2
1 (5%)
119
Sample NA1
prolactin-induced protein
4505821
16
8.2
10 (62%)
17127
albumin preproprotein
4502027
71
5.9
36 (61%)
9157
semenogelin II precursor
4506885
65
9
22 (39%)
7469
semenogelin I isoform b preproprotein
38049014
45
9.2
19 (42%)
2622
prostate specific antigen isoform 1 preproprotein
4502173
29
7.6
14 (67%)
5287
lactotransferrin
54607120
80
8.5
19 (40%)
2696
zinc alpha-2-glycoprotein 1
4502337
34
5.7
9 (38%)
1904
epididymal secretory protein E1 precursor
5453678
16
7.5
6 (68%)
1228
extracellular matrix protein 1 isoform 1 precursor
221316614
62
6.2
6 (22%)
635
serine proteinase inhibitor, clade A, member 1
50363217
46
5.3
8 (27%)
616
tissue inhibitor of metalloproteinase 1 precursor
4507509
23
8.4
2 (19%)
487
prosaposin isoform a preproprotein
11386147
59
5
4 (15%)
475
beta 2 microglobulin precursor
4757826
13
6
2 (21%)
400
fibronectin 1 isoform 3 preproprotein
16933542
262
5.4
7 (5%)
398
cystatin C precursor
4503107
16
9
3 (26%)
340
cystatin S precursor
4503109
16
4.9
2 (20%)
261
mucin 6, gastric isoform 1
89033736
185
6.3
4 (5%)
238
prostaglandin (H2) D-isomerase
32171249
21
7.6
1 (8%)
227
prostatic acid phosphatase precursor
6382064
44
5.8
4 (8%)
189
protein tyrosine phosphatase, receptor type, sigma isoform 1 precursor
104487006
218
6.1
5 (5%)
180
transferrin
4557871
79
6.8
3 (17%)
174
clusterin isoform 1
42716297
58
6.2
4 (11%)
171
cathepsin D preproprotein
4503143
45
6.1
1 (4%)
149
galectin 3 binding protein
5031863
66
5.1
5 (14%)
101
Sample NA2
prolactin-induced protein
4505821
16
8.2
12 (76%)
21197
semenogelin II precursor
4506885
65
9
18 (36%)
9137
semenogelin I isoform b preproprotein
38049014
45
9.2
13 (33%)
1777
albumin preproprotein
4502027
71
5.9
26 (55%)
7695
prostate specific antigen isoform 1 preproprotein
4502173
29
7.6
16 (67%)
4963
zinc alpha-2-glycoprotein 1
4502337
34
5.7
13 (44%)
3134
lactotransferrin
54607120
80
8.5
24 (46%)
3105
epididymal secretory protein E1 precursor
5453678
16
7.5
5 (68%)
1276
prosaposin isoform a preproprotein
11386147
59
5
7 (26%)
662
tissue inhibitor of metalloproteinase 1 precursor
4507509
23
8.4
3 (29%)
660
serine proteinase inhibitor, clade A, member 1
50363217
46
5.3
5 (20%)
612
extracellular matrix protein 1 isoform 1 precursor
4758236
62
6.2
7 (22%)
577
cystatin C precursor
4503107
16
9
3 (26%)
548
beta 2 microglobulin precursor
4757826
13
6
2 (21%)
443
prostatic acid phosphatase precursor
6382064
44
5.8
8 (18%)
410
cathepsin D preproprotein
4503143
45
6.1
5 (25%)
375
clusterin isoform 1
42716297
58
6.2
2 (7%)
308
DJ-1 protein
31543380
20
6.3
2 (26%)
279
carboxypeptidase E preproprotein
4503009
53
5
4 (19%)
278
galectin 3 binding protein
5031863
66
5.1
5 (14%)
266
cystatin S precursor
4503109
16
4.9
6 (64%)
212
CD177 molecule
110735433
47
5.6
2 (9%)
199
mucin 6, gastric isoform 1
89033736
185
6.3
3 (4%)
196
fibronectin 1 isoform 3 preproprotein
16933542
262
5.4
4 (4%)
172
secretory leukocyte peptidase inhibitor precursor
4507065
15
9.1
2 (28%)
162
cathepsin B preproprotein
4503139
38
5.8
3 (12%)
127
Sample NA3
prolactin-induced protein
4505821
16
8.2
5 (37%)
6642
semenogelin II precursor
4506885
65
9
6 (9%)
5126
albumin preproprotein
4502027
71
5.9
7 (17%)
2077
prosaposin isoform a preproprotein
11386147
59
5
2 (8%)
438
mucin 6, gastric isoform 1
89033736
185
6.3
3 (2%)
269
epididymal secretory protein E1 precursor
5453678
16
7.5
2 (21%)
210
zinc alpha-2-glycoprotein 1
4502337
34
5.7
3 (24%)
203
prostate specific antigen isoform 1 preproprotein
4502173
29
7.6
3 (13%)
141
clusterin isoform 1
42716297
58
6.2
3 (10%)
117
Sample NA4
prolactin-induced protein
4505821
16
8.2
10(76%)
22296
semenogelin II precursor
4506885
65
9
16 (30%)
11486
semenogelin I isoform b preproprotein
38049014
45
9.2
13 (33%)
3038
prostate specific antigen isoform 1 preproprotein
4502173
29
7.6
14 (67%)
3631
zinc alpha-2-glycoprotein 1
4502337
34
5.7
11 (38%)
3260
lactotransferrin
54607120
80
8.5
16 (45%)
2926
prosaposin isoform a preproprotein
11386147
59
5
5 (20%)
773
epididymal secretory protein E1 precursor
5453678
16
7.5
3 (39%)
533
serine proteinase inhibitor, clade A, member 1
50363217
46
5.3
4 (12%)
506
extracellular matrix protein 1 isoform 1 precursor
4758236
62
6.2
4 (17%)
454
beta 2 microglobulin precursor
4757826
13
6
2 (21%)
388
tissue inhibitor of metalloproteinase 1 precursor
4507509
23
8.4
3 (29%)
351
cystatin S precursor
4503109
16
4.9
5 (48%)
321
cystatin C precursor
4503107
16
9
2 (26%)
280
cathepsin D preproprotein
4503143
45
6.1
2 (11%)
200
cathepsin B preproprotein
4503139
38
5.8
2 (10%)
186
carboxypeptidase E preproprotein
4503009
53
5
3 (11%)
162
Sample OA1
prolactin-induced protein
4505821
16
8.2
12 (77%)
22670
semenogelin II precursor
4506885
65
9
19(32%)
13764
semenogelin I isoform b preproprotein
38049014
45
9.2
15 (27%)
6586
albumin preproprotein
4502027
71
5.9
26 (51%)
7715
lactotransferrin
54607120
80
8.5
28 (54%)
5063
prostate specific antigen isoform 1 preproprotein
4502173
29
7.6
11 (64%)
3309
zinc alpha-2-glycoprotein 1
4502337
34
5.7
9 (40%)
3298
ankyrin repeat domain 11
56676397
299
6.7
3 (1%)
1056
PREDICTED: mucin 6, gastric isoform 1
89033736
185
6.3
10 (14%)
808
epididymal secretory protein E1 precursor
5453678
16
7.5
7 (70%)
635
clusterin isoform 1
42716297
58
6.2
4 (13%)
512
fibronectin 1 isoform 2 preproprotein
47132551
269
5.3
10 (7%)
503
extracellular matrix protein 1 isoform 1 precursor
4758236
62
6.2
5 (28%)
420
prosaposin isoform a preproprotein
11386147
59
5
4 (18%)
407
prostatic acid phosphatase precursor
6382064
44
5.8
9 (28%)
365
tissue inhibitor of metalloproteinase 1 precursor
4507509
23
8.4
4 (35%)
337
beta 2 microglobulin precursor – 1 peptide
4757826
13
6
1 (18%)
262
serine proteinase inhibitor, clade A, member 1
50363217
46
5.3
4 (12%)
242
transferrin
4557871
79
6.8
3 (4%)
211
cathepsin D preproprotein
4503143
45
6.1
2 (11%)
206
cystatin C precursor
4503107
16
9
5 (52%)
199
cystatin S precursor
4503109
16
4.9
6 (68%)
198
secretory leukocyte peptidase inhibitor precursor −1 peptide
4507065
15
9.1
1 (18%)
175
carboxypeptidase E preproprotein
4503009
53
5
2 (8%)
123
galectin 3 binding protein
5031863
66
5.1
3 (8%)
105
cathepsin B preproprotein
4503139
38
5.8
2 (12%)
95
expressed in prostate and testis
19923082
14
8.2
1 (10%)
86
macrophage migration inhibitory factor – 1 peptide
4505185
12
7.7
1 (9%)
84
prostaglandin (H2) D-isomerase −1 peptide
32171249
21
7.6
1 (8%)
75
Sample OA2
prolactin-induced protein
4505821
16
8.2
8 (51%)
13511
semenogelin II precursor
4506885
65
9
11 (18%)
6235
albumin preproprotein
4502027
71
5.9
10 (23%)
1848
cystatin S precursor
4503109
16
4.9
3 (28%)
522
prostate specific antigen isoform 4 preproprotein
71834855
24
7
4 (25%)
354
prosaposin isoform a preproprotein
11386147
59
5
1 (2%)
324
clusterin isoform 1
42716297
58
6.2
3 (10%)
308
mucin 6, gastric isoform 1
89033736
185
6.3
2 (1%)
306
zinc alpha-2-glycoprotein 1
4502337
34
5.7
4 (17%)
291
epididymal secretory protein E1 precursor
5453678
16
7.5
3 (38%)
184
ankyrin repeat domain 11
56676397
299
6.7
3 (1%)
133
carboxypeptidase E preproprotein
4503009
53
5
2 (8%)
121
lactotransferrin precursor
54607120
80
8.5
3 (9%)
115
extracellular matrix protein 1 isoform 1 precursor
4758236
62
6.2
1 (5%)
108
galectin 3 binding protein
5031863
66
5.1
1 (2%)
98
cathepsin D preproprotein
4503143
45
6.1
2 (13%)
95
lactamase, beta isoform a
26051231
61
8.7
2 (10%)
90
prostatic acid phosphatase precursor
6382064
44
5.8
1 (4%)
78
Sample ON
prolactin-induced protein
4505821
16
8.2
9 (69%)
33212
semenogelin II precursor
4506885
65
9
20 (35%)
10703
semenogelin I isoform b preproprotein
38049014
45
9.2
17 ((38%)
2722
albumin preproprotein
4502027
71
5.9
25 (52%)
9519
prostate specific antigen isoform 1 preproprotein
4502173
29
7.6
14 (62%)
6487
zinc alpha-2-glycoprotein 1
4502337
34
5.7
9 (38%)
5967
lactotransferrin precursor
54607120
80
8.5
18(40%)
3770
serine proteinase inhibitor, clade A, member 1
50363217
46
5.3
4 (15%)
1138
prosaposin isoform a preproprotein
11386147
59
5
6 (26%)
1014
epididymal secretory protein E1 precursor
5453678
16
7.5
3 (39%)
937
tissue inhibitor of metalloproteinase 1 precursor
4507509
23
8.4
2 (19%)
866
extracellular matrix protein 1 isoform 1 precursor
221316614
62
6.2
3 (12%)
637
beta 2 microglobulin precursor
4757826
13
6
2 (21%)
633
mucin 6, gastric
151301154
263
7.2
5 (5%)
407
fibronectin 1 isoform 3 preproprotein
16933542
262
5.4
2 (1%)
352
cathepsin D preproprotein
4503143
45
6.1
2 (11%)
334
cystatin C precursor
4503107
16
9
3 (26%)
320
carboxypeptidase E preproprotein
4503009
53
5
3 (11%)
172
clusterin isoform 1
42716297
58
6.2
2 (7%)
147
acid phosphatase, prostate short isoform precursor
6382064
44
5.8
3 (8%)
132
secretory leukocyte peptidase inhibitor precursor
4507065
15
9.1
2 (42%)
123
protein tyrosine phosphatase, receptor type, sigma isoform 1 precursor
104487006
218
6.1
4 (3%)
112
Table 2
Detailed list of classification of 35 proteins based on their presence, abundance, and differential expression
No.
Protein Names
NCBI Accession No.
UniProt Accession No.
No. of samples
Proteins present in groups
Low abundant proteins (SC ≤ 10)
Differentially Expressed Proteins (in NA, OA, and ON) compared to NN
Significant proteins in groups
1
prolactin-induced protein
4505821
P12273
12
NN(5), NA(4), OA(2), ON(1)
  
NN, NA, OA, ON
2
semenogelin II precursor
4506885
Q02383
12
NN(5), NA(4), OA(2), ON(1)
  
NN, NA, OA, ON
3
albumin preproprotein
4502027
P02768
12
NN(5), NA(4), OA(2), ON(1)
  
NN, NA, OA, ON
4
lactotransferrin
54607120
P02788
12
NN(5), NA(4), OA(2), ON(1)
  
NN, NA, OA, ON
5
epididymal secretory protein E1 precursor
5453678
P61916
12
NN(5), NA(4), OA(2), ON(1)
  
NN, NA, OA, ON
6
extracellular matrix protein 1 isoform 1 precursor
221316614
Q16610
12
NN(5), NA(4), OA(2), ON(1)
  
NN, NA, OA, ON
7
prosaposin isoform a preproprotein
11386147
P07602
12
NN(5), NA(4), OA(2), ON(1)
  
NN, NA, OA, ON
8
cathepsin D preproprotein
4503143
P07339
12
NN(5), NA(4), OA(2), ON(1)
  
NN, NA, OA, ON
9
prostate specific antigen isoform 1 preproprotein
4502173
Q546G3
12
NN(5), NA(4), OA(2), ON(1)
 
↑ in OA
NN, NA, OA, ON
10
zinc alpha-2-glycoprotein 1
4502337
P25311
12
NN(5), NA(4), OA(2), ON(1)
 
↑ in ON
NN, NA, OA, ON
11
clusterin isoform 1
42716297
P10909
12
NN(5), NA(4), OA(2), ON(1)
Low in ON
↓ in ON
NN, NA, OA
12
mucin 6, gastric
151301154
Q6W4X9
11
NN(4), NA(4), OA(2), ON(1)
 
↓ in NA
NN, NA, OA, ON
13
cystatin S precursor
4503109
P01036
11
NN(4), NA(4), OA(2), ON(1)
Low in ON
↓ in NA, OA, ON
NN, NA, OA
14
galectin 3 binding protein
5031863
Q08380
11
NN(5), NA(3), OA(2), ON(1)
Low in OA and ON
↓ in OA, ON
NN, NA
15
semenogelin I isoform b preproprotein
38049014
P04279
10
NN(3), NA(4), OA(2), ON(1)
 
↑ in OA
NN, NA, OA, ON
16
prostatic acid phosphatase precursor
6382064
P15309
10
NN(4), NA(3), OA(2), ON(1)
Low in ON
↓in NA, ON
NN, NA, OA
17
cystatin C precursor
4503107
P01034
9
NN(4), NA(3), OA(1), ON(1)
 
↓in OA
NN, NA, OA, ON
18
tissue inhibitor of metalloproteinase 1 precursor
4507509
Q6FGX5
8
NN(3), NA(3), OA(1), ON(1)
 
↑ in ON
NN, NA, OA, ON
19
beta 2 microglobulin precursor
4757826
P61769
8
NN(3), NA(3), OA(1), ON(1)
Low in OA
↓ in OA; Up in ON
NN, NA, ON
20
DJ-1 protein
31543380
Q99497
6
NN(2), NA(3), ON(1)
 
↑ in NA, ON
NN, NA, ON
21
ankyrin repeat domain 11
56676397
Q6UB99
4
NA(1), OA(2), ON(1)
Low in NA and ON
↓ in OA, ON
OA
22
orosomucoid 1 precursor
167857790
P02763
2
NN(2), NA(1)
Low in NA
↓in NA
NN
23
serine proteinase inhibitor, clade A, member 1
50363217
P01009
8
NN(3), NA(3), OA(1), ON(1)
 
↑ in NA,ON; ↓ in OA
NA, OA, ON
24
transferrin
4557871
Q06AH7
6
NN(2), NA(3), OA(1)
Low abundant
↑ in NA, OA
NONE
25
secretory leukocyte peptidase inhibitor precursor
4507065
P03973
5
NN(1), NA(3), OA(1)
Low abundant
↑ in NA, OA
NONE
26
ubiquitin and ribosomal protein S27a precursor
4506713
P62979
4
NN(2), NA(1), OA(1)
Low abundant
↓ in NA, OA
NONE
27
protein tyrosine phosphatase, receptor type, sigma isoform 1 precursor
104487006
Q13332
4
NN(1), NA(2), ON(1)
Low abundant
↑ in NA, ON
NONE
28
acidic epididymal glycoprotein-like 1 isoform 1 precursor
25121982
P54107
3
NN(2), NA(1)
Low abundant
↓in NA
NONE
29
prostaglandin H2 D-isomerase
32171249
P41222
5
NN(2), NA(2), OA(1)
Low abundant
 
NONE
30
cathepsin B preproprotein
4503139
P07858
6
NN(3), NA(3)
Low abundant
 
NONE
31
expressed in prostate and testis
19923082
Q8WXA2
4
NN(2), NA(1), OA(1)
Low abundant
 
NONE
32
orosomucoid 2
4505529
P19652
1
NN(1)
Low abundant
 
NONE
33
CD177 molecule
110735433
Q8N6Q3
3
NA(1), OA(1), ON(1n with (1))
Low abundant
 
NONE
34
carboxypeptidase E preproprotein
4503009
P16870
9
NN(3), NA(3), OA(2), ON(1)
Low in OA and ON
 
NN, NA
35
fibronectin 1 isoform 2 preproprotein
47132551
P02751
10
NN(4), NA(4), OA(1), ON(1)
Low in ON
 
NN, NA, OA
NN = normal sperm count and normal morphology; NA = normal sperm count and abnormal morphology; ON = oligozoospermia and normal morphology; OA = oligozoospermia and abnormal morphology; number in the parenthesis indicates the number of samples.

Identification of the common proteins

Our analyses revealed a set of 11 proteins that were common to all the samples in the 4 groups (Table 2). Prolactin induced protein (PIP), semenogelin II (SgII) precursor, albumin preprotein, lactotransferrin, epididymal secretory protein E1 precursor, extracellular matrix protein 1 isoform 1 precursor, prosaposin isoform A preprotein, cathepsin D preprotein, prostate specific antigen isoform 1 preprotein, zinc alpha-2 glycoprotein 1, and clusterin isoform 1 were the common proteins identified.

Identification of differentially expressed proteins

As shown in Figure 1, the DEP list encompassed proteins that overlapped with other categories (common, unique, low abundant and significant). The common proteins that were also differentially expressed included prostate specific antigen isoform I preprotein; zinc alpha-2-glycoprotein 1 and clusterin isoform 1. Five low abundant proteins (transferrin; secretory leukocyte peptidase inhibitor precursor; ubiquitin and ribosomal protein S27a precursor; protein tyrosine phosphatase receptor type, sigma isoform 1 precursor, and acidic epididymal glycoprotein-like 1 isoform 1 precursor) were included as differentially expressed because their NSC ratio comparison met the 2-fold cutoff criteria. Of the 20 differentially expressed proteins, mucin 6, gastric; orosomucoid 1 precursor and acidic epididymal glycoprotein-like isoform 1 precursor were unique proteins that were down regulated in the NA group. The proteins identified as unique and upregulated in the OA group were: prostate specific antigen isoform 1 preprotein; semenogelin I isoform b preprotein. Cystatin C precursor was found to be downregulated in the OA group. The ON group showed an upregulation of two unique proteins (zinc alpha-2 glycoprotein 1 and tissue inhibitor of metalloproteinase 1 precursor); while clusterin 1 was downregulated in this group.
Some unique proteins were absent in some of the groups but were differentially expressed in other groups. These proteins included the DJ-1 protein, which was absent in the OA groups, whereas the ankyrin repeat domain 11 was absent in the NN group. Also included in this category was orosomucoid 1 precursor, which was found in significant abundance in the NN samples but in low abundance in NA sample.

Identification of the low abundant proteins

Many of the identified proteins were low abundant proteins (SC ≤10) (Table 2). Some of these proteins were restricted to a particular group while they were absent in other groups. Transferrin, secretory leukocyte peptidase inhibitor precursor, ubiquitin and ribosomal protein S27 a precursor, prostaglandin H2 D isomerase were some of the proteins that were absent in ON group. The CD177 molecule was absent only in the NN group; while orosomucoid 2 was present only in the NN. Protein tyrosine phosphatase, receptor type, sigma isoform 1 precursor and acidic epididymal glycoprotein - like 1 isoform 1 precursor protein were absent in the OA group.

Cellular distribution and significant biological processes for proteins in four groups

The functional analysis revealed that most of the significant proteins in each of the four groups (NN, NA, OA, and ON) had a predominant cellular distribution in the extracellular region followed by their presence in the intracellular organelles (Figure 3). The distribution of proteins in the NA group was comparable in most of the cases to the NN group but was different from the ON and OA groups. The OA group showed only ~15% of the proteins localized in the plasma membrane region compared to the other groups, with the maximum number of proteins (~20%) localized in the lysosomal and vacuolar regions. The ON group showed the least distribution of proteins in the nuclear region compared to the extracellular region.
The functional analysis of the significant proteins in each of the groups revealed that most of the proteins involved in the biological process were regulatory in function (Figure 4). Based on the distribution pattern of the regulatory proteins, the OA groups showed the least involvement of proteins (60%) in regulation compared with 70% - 75% seen in the NN, NA and ON groups. A smaller number of proteins were involved in other functional processes such as protein complex assembly, cell morphogenesis, membrane organization, protein maturation and trafficking in all the 4 groups. Interestingly, none of the proteins in the ON group were involved in any of these processes. Importantly, of all the major processes represented, the OA groups showed the lowest distribution of signal transduction proteins (15%) and had little or no role in neurological system processing, membrane organization and protein maturation.

Comparison of cellular distribution and biological processes amongst the common, DEP, and low abundant proteins

A detailed evaluation of the cellular localization of the common, DEP and low abundant proteins is shown in Figure 5. A higher distribution of the common proteins was seen in the majority of cellular compartments compared to DEP and low abundance proteins. The extracellular region showed the highest distribution (91%) of the common proteins whereas they were absent in the ribosomal and endosomal regions. Higher distribution of differentially expressed proteins was seen in the cytosolic and Golgi regions compared to the common or low abundance proteins. The low abundant proteins were absent in the protein complex and secretory granular region but their localization was found to be high in the nuclear and endosomal regions.
A comparative analysis of the proteins involved in various biological processes in the three groups are shown in Figure 6. The proteins commonly expressed in all 4 groups played a significant role in many of the biological processes such as cellular development, molecular transport, and stress response, interactions with cells and organisms, cellular processes and in processes relating to the immune system. Compared with the common proteins, DEP were comparable for the regulatory processes, but were reduced in all biological processes. Higher distribution was seen in protein metabolic process, vesicle mediated transport, defense response and cellular protein modification process. The low abundant proteins were seen to be involved mainly in protein metabolism, vesicle-mediated transport and defense response.

Pathways and network analysis using IPA and metacore™

Based on the dataset derived from common, DEP and low abundance proteins, pathways, biological functions and networks of interactions were derived utilizing the two proprietary pathway packages, IPA and Metacore™. The important processes affected by common proteins were lipid metabolism (epididymal secretory protein E1 precursor, prosaposin isoform A preprotein, clusterin isoform 1, lactotransferrin and cathepsin D preprotein), cell death and survival (cathepsin D preprotein, lactotransferrin, clusterin isoform 1, prosaposin isoform A preprotein and prostate specific antigen isoform 1 preprotein), and cellular development (clusterin isoform 1, prostate specific antigen isoform 1 preprotein, lactotransferrin, extracellular matrix protein 1 isoform 1 precursor, cathepsin D preprotein and epididymal secretory protein E1 precursor).
The important processes affected by DEP showed a higher involvement in carbohydrate metabolism and nephrosis (ankyrin repeat domain 11, beta 2 microglobulin (B2MG) precursor, clusterin isoform 1, cystatin C precursor, prostate specific antigen isoform 1 preprotein, DJ-1 protein, protein tyrosine phosphatase, receptor type, sigma isoform 1 precursor, transferrin). The major pathways involved are proteolysis (extracellular matrix; ECM), remodeling and connective tissue degradation, immune response, clathrin-mediated endocytosis signaling, lipid antigen presentation by CD1, and intrinsic prothrombin activation pathway. Similarly, in the low abundant proteins the top biological functions included the cellular development, growth proliferation, DNA replication, recombination, and repair (prostaglandin (H2) D-isomerase, protein tyrosine phosphatase, receptor type, sigma isoform 1 precursor and transferrin).
We also studied the major biological functions of the DEP in each of the 3 groups and found that free radical scavenging was the topmost function in the NA group, while cell-to-cell signaling and interaction were seen in all 3 groups. Genes that encode for 7 differentially expressed proteins (cysteine-rich secretory protein 1, clusterin, prostatic acid phosphatase (PAP), mucin 6, prostate specific antigen (PSA), zinc alpha-2-glycoprotein 1, and DJ-1) are known to be regulated by androgen receptor. The transcriptional network showed the activation of prostate induction by the androgen receptor signaling pathway. DJ-1 protein, protein tyrosine phosphatase, receptor type, sigma isoform 1 precursor and transferrin were observed to interact with other proteins in the pathway database and affect processes related to cellular function and maintenance. Similarly, in the OA group, prostate specific antigen isoform 1 preprotein and transferrin formed the topmost network, encompassing key processes such as gene expression, tissue morphology and cell cycle. The ON group showed immunological disease, antigen presentation, cell-to-cell signaling and interaction (B2MG precursor, DJ-1 protein, receptor type, sigma isoform 1 precursor) as the key processes affected in its topmost network

Discussion

Seminal plasma is a mixture of secretions of several male accessory glands, including prostate, seminal vesicles, epididymis and Cowper’s gland. Prostate gland is a major contributor to seminal plasma. It is a very rich source of protein with concentration ranges from 35 to 55 g/l [9, 10]. It provides a safe environment for spermatozoa to carry out their physiological functions. Understanding the protein profile of human seminal plasma is important because it has a profound impact on sperm physiology and thus may affect sperm functioning [31].
In this novel study, we identified 35 proteins based on SEQUEST scoring in the seminal plasma of men with varying semen parameters and categorized them into common, differentially expressed, and low abundant proteins. The large variation in the number of proteins identified by any given technique depends mainly on the sample preparation and mass spectrometry technology available [3236]. Recently, the LTQ-Orbitrap mass spectrometer has become the cutting-edge instrument for LC/MDS/MS based approaches to characterize the seminal proteome. In our study, we used in-solution digestion of proteins with the online LC-MS system. Seminal plasma from different subsets was pooled to form 4 distinct study groups. There are numerous studies in the proteomic literature that refer to the benefits of pooling samples where it may not be feasible to analyze individual samples due to limitations of the sample or the study design [8, 17, 37, 38].
Of the 11 proteins found in all the samples, 9 were associated with sperm function, and the common proteins comprised the majority of the secretions of the prostate gland, the seminal vesicles and epididymis. Some of the proteins or their isoforms detected in the seminal plasma were zinc alpha-2-glycoprotein 1, clusterin, lactotransferrin, prostate specific antigen. These were similar to those reported by Utleg et al. [39].
Prostate specific antigen is a serine protease that cleaves semenogelin by hydrolysis and thus liquefies the semen coagulum and facilitates sperm motility and capacitation [40, 41]. Our study showed that prostate specific antigen isoform I preprotein was one of the common proteins, thus indicating its importance in all the 4 groups. Prolactin-induced protein (PIP) and Sg II are important common proteins that have a profound impact on sperm physiology. PIP has specificity to fibronectin and constitutes about 1% of seminal coagulum [42]. It may play a vital role in fibronectin breakdown during liquefaction. Viscous samples have been reported to show reduced amounts of PIP and PIP precursor, which may also be a contributory factor towards incomplete liquefaction [43]. Both Sg I and II are the major proteins of the coagulum. They represent 20-40% of the seminal plasma proteins. Studies have shown increased Sg concentrations in asthenozoospermic men [44, 45]. Our study showed that both prolactin and semenogelin II were in all samples but they were not differentially expressed, indicating that men with low sperm count or abnormal morphology may not be affected by these proteins—a conclusion also made by Milardi et al. [18].
Epididymal secretory protein E I precursor, albumin preprotein, lactotransferrin, extracellular matrix protein E1 precursor, prosaposin isoform a preprotein, cathepsin D preprotein were some of the commonly expressed proteins that were not differentially expressed in any of the groups, suggesting that these proteins may not play a significant role in sperm concentration or morphology.
The highest percentage of the common proteins was seen in the extracellular region (Figure 5). Human seminal plasma proteins can bind to sperm surface proteins in the ejaculate and form a protective layer around the spermatozoon [12] as well as a sperm reservoir in the oviduct [46]. It is likely that the extracellular origin of most of the common proteins may play a key role in the binding activity of the proteins. The absence of common proteins in the ribosomal and endosomal region (Figure 5) suggests a relatively low involvement in protein metabolism, as also seen by the low distribution of common proteins in the ‘protein metabolic process’ category, (Figure 6). Zinc alpha-2 glycoprotein and clusterin play a role in signal transduction while lactotransferrin is a transport and structural protein [39]. Prostate specific antigen has been shown to have enzymatic activity. Our results show a high distribution of signal transducing protein among the common proteins, suggesting the importance of clusterin, isoform 1 and zinc alpha-2 glycoprotein 1 (Figure 6). This was also confirmed from the pathway and network analysis, which also highlighted the role these proteins play in molecular transport, cell death and survival and lipid metabolism.
A clear overlap was observed for some of the differentially expressed proteins. These included the prostate specific antigen isoform 1 preprotein, zinc alpha 2 glycoprotein 1, and clusterin isoform 1. While semenogelin II precursor was seen in common proteins, the semenogelin I isoform b preprotein was found to be upregulated in the OA group. This suggests that it may contribute to the low motility seen in this group compared to other groups.
Clusterin isoform was downregulated in the ON group. This is an interesting finding, given that clusterin isoform 1 has been shown to be downregulated in prostate cancer. The proteome of the seminal fluid is largely attributed to secretions from the prostate gland, and approximately 10% is contributed by the testis and the epididymis [8].
Prostate gland is a major contributor to seminal plasma. Furthermore, one of the proteins - prostatic acid phosphatase (PAP) was significantly increased in azoospermic men compared to oligozoospermic men and asthenozoospermic men [10]. In our study, PAP levels were down regulated in the NA and ON groups. PAP levels have also been reported to correlate with sperm concentration [4749]. Patients with severe oligozoospermia (<1 × 106) were also shown to have increased levels of seminal PAP [50]. PAP is produced in the prostate gland and is present in the seminal fluid at a concentration of 1 mg/mL. It is an important tumor marker and acts as a negative growth regulator in prostate cancer [51].
A proteomic analysis of seminal fluid, rather than blood, has been proposed as as a better starting point to identify changes that may serve as specific and sensitive markers of prostate dysfunction [17]. These authors identified more than 100 proteins such as PSA, semenogelin I and II, clusterin etc. which have been shown to affect sperm quality.
The increased expression of semenogelin I in the OA group suggests that the accessory gland secretions have a profound impact on oligozoospermic men with abnormal morphology. Wang et al. reported semenogelin I and mucin were not differentially expressed and therefore had no effect in asthenozoospermic men [21]. Our study also included the differentially expressed proteins, especially DJ-1 secreted from the testis, epididymis and prostate [39, 52]. DJ-1 has a high level of expression in the testis. We found DJ-1 to be overexpressed in the NA and ON groups. We also documented that orosomucoid 1 precursor was downregulated in the NA group whereas expression of orosomucoid 2 was comparable in all groups, though it was present in low abundance. However, Wang et al. reported the overexpression of orosomucoid 1 and orosomucoid 2 in asthenozoospermic patients [21]. These proteins have also been found in high abundance in post vasectomy patients [8].
B2MG was found to be under-expressed in OA while over-expressed in the ON samples. B2MG is present in all nucleated cells. It is one of the two polypeptide chains of the major histocompatiblity complex (MHC) class I molecule. In humans B2MG is coded by the B2M gene. It is a marker of cellular immune system. It is a naturally occurring protein and can detect certain types of tumor cells in the blood and kidney, and some inflammatory and autoimmune disorders [53, 54]. In our study as well as that reported by Fung et al. [17], many of the proteins in the seminal plasma were identified to be forerunners of prostate disease, suggesting a pathogenic role for B2MG [55, 56]. Similarly high levels of B2MG were reported in the seminal plasma of azoospermic men compared to controls [10, 57, 58]. An inverse correlation was reported between B2MG levels in seminal fluid and sperm count [10].
Similary, we reported the underexpression of galectin 3 binding protein in oligozoospermic group. Galectin-3 is a carbohydrate-binding protein whose expression level has been shown to correlate with metastatic potential in a number of different types of tumors. Galectin-3 is downregulated in prostate cancer. The altered downregulation pattern of galectin-3 observed between tumor stages suggests different roles for galectin-3 in the progression of prostate cancer [59].
TIMP 1 can inhibit tumor growth, invasion and metastasis through their matrix metalloproteinases (MMP) inhibitory activity [60, 61]. TIMPs play an inhibitory role, and any imbalance between the two may result in progression of the disease [62]. TIMP was found to be over-expressed in the ON group.
Amongst the proteins that were uniquely under-expressed in the OA group was ankyrin repeat domain 11 (ANKRD11). Ankyrins function as adaptor proteins [63, 64] and play a vital role in membrane skeleton organization, ionic transport, maintenance of cell polarity as well as cell-cell adhesion regulation. Data suggest that ANKRD11 may act as a tumor suppressor [65]. It’s presence in the semen samples has not been well documented, but it is likely that its overexpression in oligozoospermic men may play a role in apoptosis. Clusterin isoform 1 can be both pro- and antiapoptotic depending upon the isoform expressed [66, 67]. It plays a key role in signal transduction and is involved in apoptosis of spermatocytes, sperm maturation, and spermiation. Low signal transducing proteins were seen in the OA group compared with the other groups, as shown in Figure 4.
Compared with the proteins involved in stress response, as elucidated from GO annotations (Figure 4), the NA and ON groups had a higher distribution of stress proteins such as DJ-1 whereas a lower distribution of this protein was seen in OA group. DJ-1 protein is a multifunctional, highly conserved antioxidant protein and is upregulated in hyperglycemia [68, 69]. It is mainly involved in the control of oxidative stress and is downregulated in the seminal plasma of asthenozoospermic men [21]. DJ-1 is activated in stress conditions, but with higher levels of stress (as seen in OA), there is depletion of antioxidant levels and low expression of DJ-1 protein. Furthermore, the major biological function that comes into focus through IPA in the NA group is free-radical scavenging activity. This further supports the fact that DJ-1 was activated in the NA group. Significant proteins were distributed in the lysosomal and vacuolar regions in higher amounts in the OA group (Figure 3), suggesting that proteins with phagocytic activity may be activated in stress conditions. Previous studies have reported reduced levels of DJ-1 in sperm in response to toxic exposure of male rats to ornidazole and epichlorhydrin [70].
Utleg et al. categorized prostatic acid phosphatase (PAP) precursor as an enzymatic protein, and the presence of this protein in our study suggests that it plays a similar role [39]. The distribution pattern of immune system response in all the groups is shown in Figure 4. It is likely that B2MG is the major protein in immune response and that low levels of this protein are seen in stress conditions. Low distribution of B2MG in DEP compared to normal and low abundant proteins further suggests that in addition to B2MG, there are other proteins that also play a key role in immune system processes. We further validated this observation from the pathway analysis, which showed that that the common protein prosaposin isoform, a preprotein, is involved in lipid antigen presentation by CD1.
We observed overlapping of differentially expressed proteins with the low abundant proteins in our study. These included transferrin, secretory leukocyte peptidase inhibitor precursor, ubiquitin and ribosomal protein S27a precursor, protein tyrosine phosphatase, receptor type, sigma isoform 1 precursor and acidic epidiymal glycoprotein- like 1 isoform 1 precursor. Of these proteins, protein tyrosine phosphatase, receptor type, sigma isoform 1 precursor, acidic epididymal glycoprotein-like isoform 1 precursor were amongst the low abundant proteins. Protein tyrosine phosphatase, receptor type, sigma isoform 1 precursor were upregulated while acidic epididymal glycoprotein-like isoform 1 precursor was down regulated in the NA group. The acidic epididymal glycoprotein like I isoform I precursor is a member of the cysteine - rich secretory protein (CRISP) family and is encoded by the gene CRISP-I. It is expressed in the epididymis and is secreted into the epididymal lumen. It binds to the post acrosomal region of the head, where it may play a role in sperm-egg fusion. The reported low abundance of acidic epididymal glycoprotein like I isoform I precursor protein is concordant with the findings of Batruch et al. who also reported its low abundance in the seminal plasma of post vasectomy patients compared to controls [8].
Transferrin is one of the serum proteins that has been characterized in the seminal plasma, but its role in male infertility is unclear [20]. Our study showed this protein was present in low levels in the NN group but was up regulated in NA and OA groups. Prostaglandin H2 D isomerase, cathepsin B preprotein, orosomucoid 2 and the CD177 molecule were the low abundant proteins that were not differentially expressed in any of the groups. In our study, CD177 was absent in the NN group but present in all the other groups although they were not differentially expressed. Our findings are consistent with previous publications that reported low concentrations of CD177 in fertile men (control samples) compared to postvasectomy men [8] but are contrary to the findings of Wang et al. who reported upregulation of CD177 in asthenozoospermic patients [21]. Cathepsin B preprotein was present in the NN and NA groups, showing its specificity to the normal sperm count while prostaglandin H2 D isomerase was absent in the ON group. Cathepsin B preprotein found in the lysosomal region is a thiol protease believed to participate in intracellular degradation. It has also been implicated in tumor invasion and metastasis. The prostaglandin (H2) D-isomerase is expressed in the testis, epididymis and prostate and is secreted into the seminal fluid. It binds small non-substrate lipophilic molecules and may act as a scavenger for harmful hydrophobic molecules. The prostaglandin (H2) D-isomerase and cathepsin B protein are potentially involved in biological processes such as vesicle-mediated transport and defense response. The low abundant proteins showed a marked distribution in the extracellular region and may play a regulatory role. The major pathways in which the low abundant proteins were involved were prostanoid biosynthesis and eicosanoid signaling and acute phase response signaling, but the distribution of signal transduction proteins was decreased in low abundant proteins.

Conclusions

In the present study, we have identified proteins that are common, unique, and differentially expressed in 4 study groups. Twenty proteins were differentially expressed in the seminal plasma of men with poor sperm quality. We have highlighted the distribution pattern of these proteins in cell organelles and described their biological processes. We have also illustrated the high involvement of proteins in cellular development signal transduction. The overexpression or underexpression of these proteins in the 4 groups illustrates their role in male infertility. Our findings from the bioinformatic analysis shows that stress proteins such as DJ-1 are differentially regulated and expressed in the different study groups, suggesting that some of these proteins may serve as a potential biomarkers in identifying the mechanistic role in men with poor sperm quality.

Acknowledgements

This study was supported by Cleveland Clinic, Research Program Committee. Authors wish to thank the Cleveland Clinic Andrology laboratory personnel for their help with scheduling of subjects used in this study. This research project was supported in part by funds from the Cleveland Clinic Research Program Committee and the Center for Reproductive Medicine. Visit of GM supported in part by the INSPIRE fellowship from the Department of Science and Technology, New Delhi, India.
Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License ( https://​creativecommons.​org/​licenses/​by/​2.​0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

RS participated in the study conception/design, review of the data and writing of the manuscript and final approval. BW, SY and BG contributed to data interpretation and participated in the paper redaction; GM participated in the review of the data and writing of the manuscript. AA contributed to the study design, and review of the data. RJ participated in organizing the subject information and review of the study findings. ES provided the subjects and participated in the study design. All authors read and approved the final manuscript.
Literatur
1.
Zurück zum Zitat The Practice Committee of the American Society for Reproductive Medicine: Diagnostic evaluation of the infertile male: a committee opinion. Fertil Steril. 2012, 98: 294-301.CrossRef The Practice Committee of the American Society for Reproductive Medicine: Diagnostic evaluation of the infertile male: a committee opinion. Fertil Steril. 2012, 98: 294-301.CrossRef
2.
Zurück zum Zitat Kruger TF, Menkveld R, Stander FS, Lombard CJ, Van der M, van Zyle JA, Smith K: Sperm morphologic features as a prognostic factor in in vitro fertilization. Fertil Steril. 1986, 46: 1118-1123.PubMed Kruger TF, Menkveld R, Stander FS, Lombard CJ, Van der M, van Zyle JA, Smith K: Sperm morphologic features as a prognostic factor in in vitro fertilization. Fertil Steril. 1986, 46: 1118-1123.PubMed
3.
Zurück zum Zitat Kruger TF, Acosta AA, Simmons KF, Swanson RJ, Matta JF, Veeck LL, Morshedi M, Brugo S: New method of evaluating sperm morphology with predictive value for human in vitro fertilization. Urology. 1987, 30: 248-251. 10.1016/0090-4295(87)90246-9.CrossRefPubMed Kruger TF, Acosta AA, Simmons KF, Swanson RJ, Matta JF, Veeck LL, Morshedi M, Brugo S: New method of evaluating sperm morphology with predictive value for human in vitro fertilization. Urology. 1987, 30: 248-251. 10.1016/0090-4295(87)90246-9.CrossRefPubMed
4.
Zurück zum Zitat Guzick DS, Overstreet JW, Factor-Litvak P, Brazil CK, Nakajima ST, Coutifaris C, Carson SA, Cisneros P, Steinkampf MP, Hill JA, Xu D, Vogel DL: Sperm morphology, motility, and concentration in fertile and infertile men. N Engl J Med. 2001, 345: 1388-1393. 10.1056/NEJMoa003005.CrossRefPubMed Guzick DS, Overstreet JW, Factor-Litvak P, Brazil CK, Nakajima ST, Coutifaris C, Carson SA, Cisneros P, Steinkampf MP, Hill JA, Xu D, Vogel DL: Sperm morphology, motility, and concentration in fertile and infertile men. N Engl J Med. 2001, 345: 1388-1393. 10.1056/NEJMoa003005.CrossRefPubMed
5.
Zurück zum Zitat Agarwal A, Sharma RK, Nallella KP, Thomas AJ, Alvarez JG, Sikka SC: Reactive oxygen species as an independent marker of male factor infertility. Fertil Steril. 2006, 86: 878-885. 10.1016/j.fertnstert.2006.02.111.CrossRefPubMed Agarwal A, Sharma RK, Nallella KP, Thomas AJ, Alvarez JG, Sikka SC: Reactive oxygen species as an independent marker of male factor infertility. Fertil Steril. 2006, 86: 878-885. 10.1016/j.fertnstert.2006.02.111.CrossRefPubMed
6.
Zurück zum Zitat Saleh RA, Agarwal A, Nada EA, El-Tonsy MH, Sharma RK, Meyer A, Nelson DR, Thomas AJ: Negative effects of increased sperm DNA damage in relation to seminal oxidative stress in men with idiopathic and male factor infertility. Fertil Steril. 2003, 79: 1597-1605.CrossRefPubMed Saleh RA, Agarwal A, Nada EA, El-Tonsy MH, Sharma RK, Meyer A, Nelson DR, Thomas AJ: Negative effects of increased sperm DNA damage in relation to seminal oxidative stress in men with idiopathic and male factor infertility. Fertil Steril. 2003, 79: 1597-1605.CrossRefPubMed
7.
Zurück zum Zitat Sharma R, Agarwal A: Spermatogenesis: an overview. Human sperm chromatin: structure and function. Sperm chromatin. Biological and clinical applications in male infertility and assisted reproduction. Edited by: Zini A, Agarwal A. 2012, Springer Science + Business Media, LLC, 19-44. Sharma R, Agarwal A: Spermatogenesis: an overview. Human sperm chromatin: structure and function. Sperm chromatin. Biological and clinical applications in male infertility and assisted reproduction. Edited by: Zini A, Agarwal A. 2012, Springer Science + Business Media, LLC, 19-44.
8.
Zurück zum Zitat Batruch I, Lecker I, Kagedan D, Smith CR, Mullen BJ, Grober E, Lo KC, Diamandis EP, Jarvi KA: Proteomic analysis of seminal plasma from normal volunteers and post-vasectomy patients identifies over 2000 proteins and candidate biomarkers of the urogenital system. J Proteome Res. 2011, 10: 941-953. 10.1021/pr100745u.CrossRefPubMed Batruch I, Lecker I, Kagedan D, Smith CR, Mullen BJ, Grober E, Lo KC, Diamandis EP, Jarvi KA: Proteomic analysis of seminal plasma from normal volunteers and post-vasectomy patients identifies over 2000 proteins and candidate biomarkers of the urogenital system. J Proteome Res. 2011, 10: 941-953. 10.1021/pr100745u.CrossRefPubMed
9.
Zurück zum Zitat Pilch B, Mann M: Large-scale and high-confidence proteomic analysis of human seminal plasma. Genome Biol. 2006, 7 (5): R40-10.1186/gb-2006-7-5-r40.PubMedCentralCrossRefPubMed Pilch B, Mann M: Large-scale and high-confidence proteomic analysis of human seminal plasma. Genome Biol. 2006, 7 (5): R40-10.1186/gb-2006-7-5-r40.PubMedCentralCrossRefPubMed
10.
Zurück zum Zitat Davalieva K, Kiprijanovska S, Noveski P, Plaseski T, Kocevska B, Broussard C, Plaseska-Karanfilska D: Proteomic analysis of seminal plasma in men with different spermatogenic impairment. Andrologia. 2012, 44: 256-264. 10.1111/j.1439-0272.2012.01275.x.CrossRefPubMed Davalieva K, Kiprijanovska S, Noveski P, Plaseski T, Kocevska B, Broussard C, Plaseska-Karanfilska D: Proteomic analysis of seminal plasma in men with different spermatogenic impairment. Andrologia. 2012, 44: 256-264. 10.1111/j.1439-0272.2012.01275.x.CrossRefPubMed
11.
Zurück zum Zitat Primakoff P, Myles DG: Penetration, adhesion, and fusion in mammalian sperm-egg interaction. Science. 2002, 296: 2183-2185. 10.1126/science.1072029.CrossRefPubMed Primakoff P, Myles DG: Penetration, adhesion, and fusion in mammalian sperm-egg interaction. Science. 2002, 296: 2183-2185. 10.1126/science.1072029.CrossRefPubMed
12.
Zurück zum Zitat Varilová T, Seménková H, Horák P, Madera M, Pacáková V, Tichá M, Stulík K: Affinity liquid chromatography and capillary electrophoresis of seminal plasma proteins. J Sep Sci. 2006, 29: 1110-1115. 10.1002/jssc.200500405.CrossRefPubMed Varilová T, Seménková H, Horák P, Madera M, Pacáková V, Tichá M, Stulík K: Affinity liquid chromatography and capillary electrophoresis of seminal plasma proteins. J Sep Sci. 2006, 29: 1110-1115. 10.1002/jssc.200500405.CrossRefPubMed
13.
Zurück zum Zitat Kelly RW: Immunosuppressive mechanisms in semen: implications for contraception. Hum Reprod. 1995, 10: 1686-1693.PubMed Kelly RW: Immunosuppressive mechanisms in semen: implications for contraception. Hum Reprod. 1995, 10: 1686-1693.PubMed
14.
Zurück zum Zitat Nishimune Y, Tanaka H: Infertility caused by polymorphisms or mutations in spermatogenesis-specific genes. J Androl. 2006, 27: 326-334. 10.2164/jandrol.05162.CrossRefPubMed Nishimune Y, Tanaka H: Infertility caused by polymorphisms or mutations in spermatogenesis-specific genes. J Androl. 2006, 27: 326-334. 10.2164/jandrol.05162.CrossRefPubMed
15.
Zurück zum Zitat Mengual L, Ballescá JL, Ascaso C, Oliva R: Marked differences in protamine content and P1/P2 ratios in sperm cells from percoll fractions between patients and controls. J Androl. 2003, 24: 438-447.PubMed Mengual L, Ballescá JL, Ascaso C, Oliva R: Marked differences in protamine content and P1/P2 ratios in sperm cells from percoll fractions between patients and controls. J Androl. 2003, 24: 438-447.PubMed
16.
Zurück zum Zitat Aoki VW, Moskovtsev SI, Willis J, Liu L, Mullen JB, Carrell DT: DNA integrity is compromised in protamine-deficient human sperm. J Androl. 2005, 26: 741-748. 10.2164/jandrol.05063.CrossRefPubMed Aoki VW, Moskovtsev SI, Willis J, Liu L, Mullen JB, Carrell DT: DNA integrity is compromised in protamine-deficient human sperm. J Androl. 2005, 26: 741-748. 10.2164/jandrol.05063.CrossRefPubMed
17.
Zurück zum Zitat Fung KY, Glode LM, Green S, Duncan MW: A comprehensive characterization of the peptide and protein constituents of human seminal fluid. Prostate. 2004, 61: 171-181. 10.1002/pros.20089.CrossRefPubMed Fung KY, Glode LM, Green S, Duncan MW: A comprehensive characterization of the peptide and protein constituents of human seminal fluid. Prostate. 2004, 61: 171-181. 10.1002/pros.20089.CrossRefPubMed
18.
Zurück zum Zitat Milardi D, Grande G, Vincenzoni F, Messana I, Pontecorvi A, De Marinis L, Castagnola M, Marana R: Proteomic approach in the identification of fertility pattern in seminal plasma of fertile men. Fertil Steril. 2012, 97: 67-73. 10.1016/j.fertnstert.2011.10.013.CrossRefPubMed Milardi D, Grande G, Vincenzoni F, Messana I, Pontecorvi A, De Marinis L, Castagnola M, Marana R: Proteomic approach in the identification of fertility pattern in seminal plasma of fertile men. Fertil Steril. 2012, 97: 67-73. 10.1016/j.fertnstert.2011.10.013.CrossRefPubMed
19.
Zurück zum Zitat Starita-Geribaldi M, Poggioli S, Zucchini M, Garin J, Chevallier D, Fenichel P, Pointis G: Mapping of seminal plasma proteins by two dimensional gel electrophoresis in men with normal and impaired spermatogenesis. Mol Hum Reprod. 2001, 7: 715-722. 10.1093/molehr/7.8.715.CrossRefPubMed Starita-Geribaldi M, Poggioli S, Zucchini M, Garin J, Chevallier D, Fenichel P, Pointis G: Mapping of seminal plasma proteins by two dimensional gel electrophoresis in men with normal and impaired spermatogenesis. Mol Hum Reprod. 2001, 7: 715-722. 10.1093/molehr/7.8.715.CrossRefPubMed
20.
Zurück zum Zitat Yamakawa K, Yoshida K, Nishikawa H, Kato T, Iwamoto T: Comparative analysis of interindividual variations in the seminal plasma proteome of fertile men with identification of potential markers for azoospermia in infertile patients. J Androl. 2007, 28: 858-865. 10.2164/jandrol.107.002824.CrossRefPubMed Yamakawa K, Yoshida K, Nishikawa H, Kato T, Iwamoto T: Comparative analysis of interindividual variations in the seminal plasma proteome of fertile men with identification of potential markers for azoospermia in infertile patients. J Androl. 2007, 28: 858-865. 10.2164/jandrol.107.002824.CrossRefPubMed
21.
Zurück zum Zitat Wang J, Wang J, Zhang HR, Shi HJ, Ma D, Zhao HX, Lin B, Li RS: Proteomic analysis of seminal plasma from asthenozoospermia patients reveals proteins that affect oxidative stress responses and semen quality. Asian J Androl. 2009, 11: 484-491. 10.1038/aja.2009.26.PubMedCentralCrossRefPubMed Wang J, Wang J, Zhang HR, Shi HJ, Ma D, Zhao HX, Lin B, Li RS: Proteomic analysis of seminal plasma from asthenozoospermia patients reveals proteins that affect oxidative stress responses and semen quality. Asian J Androl. 2009, 11: 484-491. 10.1038/aja.2009.26.PubMedCentralCrossRefPubMed
22.
Zurück zum Zitat World Health Organization: WHO laboratory manual for the examination and processing of human semen. 2010, Cambridge: World Health Organization, 5 World Health Organization: WHO laboratory manual for the examination and processing of human semen. 2010, Cambridge: World Health Organization, 5
23.
Zurück zum Zitat Hamada A, Sharma R, du Plessis SS, Willard B, Yadav SP, Sabanegh E, Agarwal A: Two-dimensional differential in-gel electrophoresis-based proteomics of male gametes in relation to oxidative stress. Fertil Steril. 2013 Hamada A, Sharma R, du Plessis SS, Willard B, Yadav SP, Sabanegh E, Agarwal A: Two-dimensional differential in-gel electrophoresis-based proteomics of male gametes in relation to oxidative stress. Fertil Steril. 2013
24.
Zurück zum Zitat Boyle E, Weng S, Gollub J, Jin H, Botstein D, Cherry JM, Sherlock G: GO:TermFinder-open source software for accessing gene ontology information and finding significantly enriched gene ontology terms associated with a list of genes. Bioinformatics. 2004, 20: 3710-3715. 10.1093/bioinformatics/bth456.PubMedCentralCrossRefPubMed Boyle E, Weng S, Gollub J, Jin H, Botstein D, Cherry JM, Sherlock G: GO:TermFinder-open source software for accessing gene ontology information and finding significantly enriched gene ontology terms associated with a list of genes. Bioinformatics. 2004, 20: 3710-3715. 10.1093/bioinformatics/bth456.PubMedCentralCrossRefPubMed
26.
Zurück zum Zitat The UniProt Consortium: Reorganizing the protein space at the universal protein resource (UniProt). Nucleic Acids Res. 2012, 40: D71-D75.PubMedCentralCrossRef The UniProt Consortium: Reorganizing the protein space at the universal protein resource (UniProt). Nucleic Acids Res. 2012, 40: D71-D75.PubMedCentralCrossRef
27.
Zurück zum Zitat Bhatia VN, Perlman DH, Costello CE, McComb ME: Software tool for researching annotations of proteins: open-source protein annotation software with data visualization. Anal Chem. 2009, 81: 9819-9823. 10.1021/ac901335x.PubMedCentralCrossRefPubMed Bhatia VN, Perlman DH, Costello CE, McComb ME: Software tool for researching annotations of proteins: open-source protein annotation software with data visualization. Anal Chem. 2009, 81: 9819-9823. 10.1021/ac901335x.PubMedCentralCrossRefPubMed
28.
Zurück zum Zitat Chunlei W, Camilo O, Jason B, Marc L, James G, Serge B, Hodge CL, James H, Jeff J, Huss JW: BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. Genome Biol. 2009, 10: R130-10.1186/gb-2009-10-11-r130.CrossRef Chunlei W, Camilo O, Jason B, Marc L, James G, Serge B, Hodge CL, James H, Jeff J, Huss JW: BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. Genome Biol. 2009, 10: R130-10.1186/gb-2009-10-11-r130.CrossRef
31.
Zurück zum Zitat Frenette G, Girouard J, Sullivan R: Comparison between epididymosomes collected in the intraluminal compartment of the bovine caput and cauda epididymidis. Biol Reprod. 2006, 75: 885-890. 10.1095/biolreprod.106.054692.CrossRefPubMed Frenette G, Girouard J, Sullivan R: Comparison between epididymosomes collected in the intraluminal compartment of the bovine caput and cauda epididymidis. Biol Reprod. 2006, 75: 885-890. 10.1095/biolreprod.106.054692.CrossRefPubMed
32.
Zurück zum Zitat Mirza SP, Olivier M: Methods and approaches for the comprehensive characterization and quantification of cellular proteomes using mass spectrometry. Physiol Genomics. 2008, 33: 3-11. 10.1152/physiolgenomics.00292.2007.PubMedCentralCrossRefPubMed Mirza SP, Olivier M: Methods and approaches for the comprehensive characterization and quantification of cellular proteomes using mass spectrometry. Physiol Genomics. 2008, 33: 3-11. 10.1152/physiolgenomics.00292.2007.PubMedCentralCrossRefPubMed
33.
Zurück zum Zitat Claverol S, Burlet-Schiltz O, Gairin JE, Monsarrat B: Characterization of protein variants and post-translational modifications: ESI-MSn analyses of intact proteins eluted from polyacrylamide gels. Mol Cell Proteomics. 2003, 2: 483-493.PubMed Claverol S, Burlet-Schiltz O, Gairin JE, Monsarrat B: Characterization of protein variants and post-translational modifications: ESI-MSn analyses of intact proteins eluted from polyacrylamide gels. Mol Cell Proteomics. 2003, 2: 483-493.PubMed
34.
Zurück zum Zitat Guthals A, Bandeira N: Peptide identification by tandem mass spectrometry with alternate fragmentation modes. Mol Cell Proteomics. 2012, 11: 550-557. 10.1074/mcp.R112.018556.PubMedCentralCrossRefPubMed Guthals A, Bandeira N: Peptide identification by tandem mass spectrometry with alternate fragmentation modes. Mol Cell Proteomics. 2012, 11: 550-557. 10.1074/mcp.R112.018556.PubMedCentralCrossRefPubMed
35.
Zurück zum Zitat Liao TT, Xiang Z, Zhu WB, Fan LQ: Proteome analysis of round-headed and normal spermatozoa by 2-D fluorescence difference gel electrophoresis and mass spectrometry. Asian J Androl. 2009, 11: 683-693. 10.1038/aja.2009.59.PubMedCentralCrossRefPubMed Liao TT, Xiang Z, Zhu WB, Fan LQ: Proteome analysis of round-headed and normal spermatozoa by 2-D fluorescence difference gel electrophoresis and mass spectrometry. Asian J Androl. 2009, 11: 683-693. 10.1038/aja.2009.59.PubMedCentralCrossRefPubMed
36.
Zurück zum Zitat VerBerkmoes NC, Bundy JL, Hauser L, Asano KG, Razumovskaya J, Larimer F, Hettich RL, Stephenson JL: Integrating “top-down” and “bottom-up” mass spectrometric approaches for proteomic analysis of shewanella oneidensis. J Proteome Res. 2002, 1: 239-52. 10.1021/pr025508a.CrossRefPubMed VerBerkmoes NC, Bundy JL, Hauser L, Asano KG, Razumovskaya J, Larimer F, Hettich RL, Stephenson JL: Integrating “top-down” and “bottom-up” mass spectrometric approaches for proteomic analysis of shewanella oneidensis. J Proteome Res. 2002, 1: 239-52. 10.1021/pr025508a.CrossRefPubMed
37.
Zurück zum Zitat Rolland AD, Lavigne R, Dauly C, Calvel P, Kervarrec C, Freour T, Evrard B, Rioux-Leclercq N, Auger J, Pineau C: Identification of genital tract markers in the human seminal plasma using an integrative genomics approach. Hum Reprod. 2013, 28: 199-209. 10.1093/humrep/des360.CrossRefPubMed Rolland AD, Lavigne R, Dauly C, Calvel P, Kervarrec C, Freour T, Evrard B, Rioux-Leclercq N, Auger J, Pineau C: Identification of genital tract markers in the human seminal plasma using an integrative genomics approach. Hum Reprod. 2013, 28: 199-209. 10.1093/humrep/des360.CrossRefPubMed
38.
Zurück zum Zitat Kagedan D, Lecker I, Batruch I, Smith C, Kaploun I, Lo K, Grober E, Diamandis EP, Jarvi KA: Characterization of the seminal plasma proteome in men with prostatitis by mass spectrometry. Clin Proteomics. 2012, 9: 2-PubMedCentralCrossRefPubMed Kagedan D, Lecker I, Batruch I, Smith C, Kaploun I, Lo K, Grober E, Diamandis EP, Jarvi KA: Characterization of the seminal plasma proteome in men with prostatitis by mass spectrometry. Clin Proteomics. 2012, 9: 2-PubMedCentralCrossRefPubMed
39.
Zurück zum Zitat Utleg AG, Yi EC, Xie T, Shannon P, White JT, Goodlett DR, Hood L, Lin B: Proteomic analysis of human prostasomes. Prostate. 2003, 56: 150-161. 10.1002/pros.10255.CrossRefPubMed Utleg AG, Yi EC, Xie T, Shannon P, White JT, Goodlett DR, Hood L, Lin B: Proteomic analysis of human prostasomes. Prostate. 2003, 56: 150-161. 10.1002/pros.10255.CrossRefPubMed
40.
Zurück zum Zitat Mitra A, Richardson RT, O'Rand MG: Analysis of recombinant human semenogelin as an inhibitor of human sperm motility. Biol Reprod. 2010, 82: 489-496. 10.1095/biolreprod.109.081331.PubMedCentralCrossRefPubMed Mitra A, Richardson RT, O'Rand MG: Analysis of recombinant human semenogelin as an inhibitor of human sperm motility. Biol Reprod. 2010, 82: 489-496. 10.1095/biolreprod.109.081331.PubMedCentralCrossRefPubMed
41.
Zurück zum Zitat Robert M, Gibbs BF, Jacobson E, Gagnon C: Characterization of prostate-specific antigen proteolytic activity on its major physiological substrate, the sperm motility inhibitor precursor/semenogelin I. Biochemistry. 1997, 36: 3811-3819. 10.1021/bi9626158.CrossRefPubMed Robert M, Gibbs BF, Jacobson E, Gagnon C: Characterization of prostate-specific antigen proteolytic activity on its major physiological substrate, the sperm motility inhibitor precursor/semenogelin I. Biochemistry. 1997, 36: 3811-3819. 10.1021/bi9626158.CrossRefPubMed
42.
Zurück zum Zitat Lilja H, Abrahamsson PA, Lundwall A: Semenogelin, the predominant protein in human semen. Primary structure and identification of closely related proteins in the male accessory sex glands and on the spermatozoa. J Biol Chem. 1989, 264: 1894-1900.PubMed Lilja H, Abrahamsson PA, Lundwall A: Semenogelin, the predominant protein in human semen. Primary structure and identification of closely related proteins in the male accessory sex glands and on the spermatozoa. J Biol Chem. 1989, 264: 1894-1900.PubMed
43.
Zurück zum Zitat Thacker S, Yadav SP, Sharma RK, Kashou A, Willard B, Zhang D, Agarwal A: Evaluation of sperm proteins in infertile men: a proteomic approach. Fertil Steril. 2011, 95: 2745-2748. 10.1016/j.fertnstert.2011.03.112.CrossRefPubMed Thacker S, Yadav SP, Sharma RK, Kashou A, Willard B, Zhang D, Agarwal A: Evaluation of sperm proteins in infertile men: a proteomic approach. Fertil Steril. 2011, 95: 2745-2748. 10.1016/j.fertnstert.2011.03.112.CrossRefPubMed
44.
Zurück zum Zitat Malm J, Hellman J, Magnusson H, Laurell CB, Lilja H: Isolation and characterization of the major gel proteins in human semen, semenogelin I and semenogelin II. Eur J Biochem. 1996, 238: 48-53. 10.1111/j.1432-1033.1996.0048q.x.CrossRefPubMed Malm J, Hellman J, Magnusson H, Laurell CB, Lilja H: Isolation and characterization of the major gel proteins in human semen, semenogelin I and semenogelin II. Eur J Biochem. 1996, 238: 48-53. 10.1111/j.1432-1033.1996.0048q.x.CrossRefPubMed
45.
Zurück zum Zitat Zhao C, Huo R, Wang FQ, Lin M, Zhou ZM, Sha JH: Identification of several proteins involved in regulation of sperm motility by proteomic analysis. Fertil Steril. 2007, 87: 436-438. 10.1016/j.fertnstert.2006.06.057.CrossRefPubMed Zhao C, Huo R, Wang FQ, Lin M, Zhou ZM, Sha JH: Identification of several proteins involved in regulation of sperm motility by proteomic analysis. Fertil Steril. 2007, 87: 436-438. 10.1016/j.fertnstert.2006.06.057.CrossRefPubMed
46.
Zurück zum Zitat Jansen S, Ekhlasi-Hundrieser M, Töpfer-Petersen E: Sperm adhesion molecules: structure and function. Cells Tissues Organs. 2001, 168: 82-92. 10.1159/000016809.CrossRefPubMed Jansen S, Ekhlasi-Hundrieser M, Töpfer-Petersen E: Sperm adhesion molecules: structure and function. Cells Tissues Organs. 2001, 168: 82-92. 10.1159/000016809.CrossRefPubMed
47.
Zurück zum Zitat Vaubourdolle M, Clavel JP, Gonzales J, Galli A: Evaluation of acid phosphatase isoenzymes in seminal fluid from normozoospermic, oligozoospermic, azoospermic and asthenoteratozoospermic men. Andrologia. 1985, 17: 598-604.CrossRefPubMed Vaubourdolle M, Clavel JP, Gonzales J, Galli A: Evaluation of acid phosphatase isoenzymes in seminal fluid from normozoospermic, oligozoospermic, azoospermic and asthenoteratozoospermic men. Andrologia. 1985, 17: 598-604.CrossRefPubMed
48.
Zurück zum Zitat Dave BN, Rindani TH: Acid phosphatase activity in human semen. Int J Fertil. 1988, 33: 45-47.PubMed Dave BN, Rindani TH: Acid phosphatase activity in human semen. Int J Fertil. 1988, 33: 45-47.PubMed
49.
Zurück zum Zitat Ziyyat A, Barraud-Lange V, Sifer C, Ducot B, Wolf JP, Soufir JC: Paradoxical increase of sperm motility and seminal carnitine associated with moderate leukocytospermia in infertile patients. Fertil Steril. 2008, 90: 2257-2263. 10.1016/j.fertnstert.2007.10.032.CrossRefPubMed Ziyyat A, Barraud-Lange V, Sifer C, Ducot B, Wolf JP, Soufir JC: Paradoxical increase of sperm motility and seminal carnitine associated with moderate leukocytospermia in infertile patients. Fertil Steril. 2008, 90: 2257-2263. 10.1016/j.fertnstert.2007.10.032.CrossRefPubMed
50.
Zurück zum Zitat Singh G, Adaikan PG, Ng YK: Is seminal prostatic acid phosphatase a reliable marker for male infertility?. Singapore Med J. 1996, 37: 598-599.PubMed Singh G, Adaikan PG, Ng YK: Is seminal prostatic acid phosphatase a reliable marker for male infertility?. Singapore Med J. 1996, 37: 598-599.PubMed
51.
Zurück zum Zitat Ostrowski W: Male accessory Sex glands. Edited by: Spring-Mills E, Hafez E. 1980, Amsterdam: Elsevier/North-Holland Biomedical Press, pp. 197-213. Ostrowski W: Male accessory Sex glands. Edited by: Spring-Mills E, Hafez E. 1980, Amsterdam: Elsevier/North-Holland Biomedical Press, pp. 197-213.
52.
Zurück zum Zitat Li R, Guo Y, Han BM, Yan X, Utleg AG, Li W, Tu LC, Wang J, Hood L, Xia S, Lin B: Proteomics cataloging analysis of human expressed prostatic secretions reveals rich source of biomarker candidates. Clin Appl. 2008, 2: 543-555. 10.1002/prca.200780159.CrossRef Li R, Guo Y, Han BM, Yan X, Utleg AG, Li W, Tu LC, Wang J, Hood L, Xia S, Lin B: Proteomics cataloging analysis of human expressed prostatic secretions reveals rich source of biomarker candidates. Clin Appl. 2008, 2: 543-555. 10.1002/prca.200780159.CrossRef
53.
Zurück zum Zitat Cooper EH, Plesner T: Beta-2-microglobulin review: its relevance in clinical oncology. Med Pediatr Oncol. 1980, 8: 323-334. 10.1002/mpo.2950080403.CrossRefPubMed Cooper EH, Plesner T: Beta-2-microglobulin review: its relevance in clinical oncology. Med Pediatr Oncol. 1980, 8: 323-334. 10.1002/mpo.2950080403.CrossRefPubMed
54.
Zurück zum Zitat Di Giovanni S, Valentini G, Carducci P, Giallonardo P: Beta-2-microglobulin is a reliable tumor marker in chronic lymphocytic leukemia. Acta Haematol. 1989, 81: 181-185. 10.1159/000205558.CrossRefPubMed Di Giovanni S, Valentini G, Carducci P, Giallonardo P: Beta-2-microglobulin is a reliable tumor marker in chronic lymphocytic leukemia. Acta Haematol. 1989, 81: 181-185. 10.1159/000205558.CrossRefPubMed
55.
Zurück zum Zitat He XH, Xu LH, Liu Y, Zeng YY: Cloning of human beta-microglobulin gene and its high expression in Escherichia coli. Sheng Wu Gong Cheng Xue Bao. 2004, 20: 99-103.PubMed He XH, Xu LH, Liu Y, Zeng YY: Cloning of human beta-microglobulin gene and its high expression in Escherichia coli. Sheng Wu Gong Cheng Xue Bao. 2004, 20: 99-103.PubMed
56.
Zurück zum Zitat Miyata T, Inagi R, Wada Y, Ueda Y, Iida Y, Takahashi M, Taniguchi N, Maeda K: Glycation of human beta 2-microglobulin in patients with hemodialysis-associated amyloidosis: identification of the glycated sites. Biochemistry. 1994, 33: 12215-12221. 10.1021/bi00206a026.CrossRefPubMed Miyata T, Inagi R, Wada Y, Ueda Y, Iida Y, Takahashi M, Taniguchi N, Maeda K: Glycation of human beta 2-microglobulin in patients with hemodialysis-associated amyloidosis: identification of the glycated sites. Biochemistry. 1994, 33: 12215-12221. 10.1021/bi00206a026.CrossRefPubMed
57.
Zurück zum Zitat Sire J, Colle A, Pinatel MC, Fellous M, Manuel Y: beta2-Microglobulin in human seminal fluid (author’s transl). Pathol Biol (Paris). 1978, 26: 392-394. Sire J, Colle A, Pinatel MC, Fellous M, Manuel Y: beta2-Microglobulin in human seminal fluid (author’s transl). Pathol Biol (Paris). 1978, 26: 392-394.
58.
Zurück zum Zitat Chard T, Parslow J, Rehmann T, Dawnay A: The concentrations of transferrin, beta 2-microglobulin, and albumin in seminal plasma in relation to sperm count. Fertil Steril. 1991, 55: 211-213.PubMed Chard T, Parslow J, Rehmann T, Dawnay A: The concentrations of transferrin, beta 2-microglobulin, and albumin in seminal plasma in relation to sperm count. Fertil Steril. 1991, 55: 211-213.PubMed
59.
Zurück zum Zitat Pacis RA, Pilat MJ, Pienta KJ, Wojno K, Raz A, Hogan V, Cooper CR: Decreased galectin-3 expression in prostate cancer. Prostate. 2000, 4: 118-123.CrossRef Pacis RA, Pilat MJ, Pienta KJ, Wojno K, Raz A, Hogan V, Cooper CR: Decreased galectin-3 expression in prostate cancer. Prostate. 2000, 4: 118-123.CrossRef
60.
Zurück zum Zitat Brew K, Dinakarpandian D, Nagase H: Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochem Biophys Acta. 2000, 1477: 267-283. 10.1016/S0167-4838(99)00279-4.PubMed Brew K, Dinakarpandian D, Nagase H: Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochem Biophys Acta. 2000, 1477: 267-283. 10.1016/S0167-4838(99)00279-4.PubMed
61.
Zurück zum Zitat Bode W, Fernandez-Catalan C, Tschesche H, Grams F, Nagase H, Maskos K: Structural properties of matrix metalloproteinases. Cell Mol Life Sci. 1999, 55: 639-652. 10.1007/s000180050320.CrossRefPubMed Bode W, Fernandez-Catalan C, Tschesche H, Grams F, Nagase H, Maskos K: Structural properties of matrix metalloproteinases. Cell Mol Life Sci. 1999, 55: 639-652. 10.1007/s000180050320.CrossRefPubMed
62.
Zurück zum Zitat Itoh Y, Binner S, Nagase H: Steps involved in activation of the complex of pro-matrix metalloproteinase 2 (progelatinase A) and tissue inhibitor of metalloproteinases (TIMP)-2 by 4-aminophenylmercuric acetate. Biochem J. 1995, 308: 645-651.PubMedCentralCrossRefPubMed Itoh Y, Binner S, Nagase H: Steps involved in activation of the complex of pro-matrix metalloproteinase 2 (progelatinase A) and tissue inhibitor of metalloproteinases (TIMP)-2 by 4-aminophenylmercuric acetate. Biochem J. 1995, 308: 645-651.PubMedCentralCrossRefPubMed
63.
Zurück zum Zitat Michaely P, Tomchick DR, Machius M, Anderson RG: Crystal structure of a 12 ANK repeat stack from human ankyrinR. EMBO J. 2002, 21: 6387-6396. 10.1093/emboj/cdf651.PubMedCentralCrossRefPubMed Michaely P, Tomchick DR, Machius M, Anderson RG: Crystal structure of a 12 ANK repeat stack from human ankyrinR. EMBO J. 2002, 21: 6387-6396. 10.1093/emboj/cdf651.PubMedCentralCrossRefPubMed
64.
Zurück zum Zitat Bennett V, Baines AJ: Spectrin and ankyrin-based pathways: metazoan inventions for integrating cells into tissues. Physiol Rev. 2001, 81: 1353-1392.PubMed Bennett V, Baines AJ: Spectrin and ankyrin-based pathways: metazoan inventions for integrating cells into tissues. Physiol Rev. 2001, 81: 1353-1392.PubMed
65.
Zurück zum Zitat Neilsen PM, Cheney KM, Li CW, Chen JD, Cawrse JE, Schulz RB, Powell JA, Kumar R, Callen DF: Identification of ANKRD11 as a p53 coactivator. J Cell Sci. 2008, 121: 3541-3552. 10.1242/jcs.026351.CrossRefPubMed Neilsen PM, Cheney KM, Li CW, Chen JD, Cawrse JE, Schulz RB, Powell JA, Kumar R, Callen DF: Identification of ANKRD11 as a p53 coactivator. J Cell Sci. 2008, 121: 3541-3552. 10.1242/jcs.026351.CrossRefPubMed
66.
Zurück zum Zitat Wong P, Borst DE, Farber D, Danciger JS, Tenniswood M, Chader GJ, Van Veen T: Increased TRPM-2/clusterin mRNA levels during the time of retinal degeneration in mouse models of retinitis pigmentosa. Biochem Cell Biol. 1994, 72: 439-446. 10.1139/o94-058.CrossRefPubMed Wong P, Borst DE, Farber D, Danciger JS, Tenniswood M, Chader GJ, Van Veen T: Increased TRPM-2/clusterin mRNA levels during the time of retinal degeneration in mouse models of retinitis pigmentosa. Biochem Cell Biol. 1994, 72: 439-446. 10.1139/o94-058.CrossRefPubMed
67.
Zurück zum Zitat Leskov KS, Klokov DY, Li J, Kinsella TJ, Boothman DA: Synthesis and functional analyses of nuclear clusterin, a cell death protein. J Biol Chem. 2003, 278: 11590-11600. 10.1074/jbc.M209233200.CrossRefPubMed Leskov KS, Klokov DY, Li J, Kinsella TJ, Boothman DA: Synthesis and functional analyses of nuclear clusterin, a cell death protein. J Biol Chem. 2003, 278: 11590-11600. 10.1074/jbc.M209233200.CrossRefPubMed
68.
Zurück zum Zitat Jain D, Jain R, Eberhard D, Eglinger J, Bugliani M, Piemonti L, Marchetti P, Lammert E: Age- and diet-dependent requirement of DJ-1 for glucose homeostasis in mice with implications for human type 2 diabetes. J Mol Cell Biol. 2012, 4: 221-230. 10.1093/jmcb/mjs025.CrossRefPubMed Jain D, Jain R, Eberhard D, Eglinger J, Bugliani M, Piemonti L, Marchetti P, Lammert E: Age- and diet-dependent requirement of DJ-1 for glucose homeostasis in mice with implications for human type 2 diabetes. J Mol Cell Biol. 2012, 4: 221-230. 10.1093/jmcb/mjs025.CrossRefPubMed
69.
Zurück zum Zitat Waanders LF, Chwalek K, Monetti M, Kumar C, Lammert E, Mann M: Quantitative proteomic analysis of single pancreatic islets. Proc Natl Acad Sci USA. 2009, 106: 18902-18907. 10.1073/pnas.0908351106.PubMedCentralCrossRefPubMed Waanders LF, Chwalek K, Monetti M, Kumar C, Lammert E, Mann M: Quantitative proteomic analysis of single pancreatic islets. Proc Natl Acad Sci USA. 2009, 106: 18902-18907. 10.1073/pnas.0908351106.PubMedCentralCrossRefPubMed
70.
Zurück zum Zitat Okada M, Matsumoto K, Niki T, Taira T, Iguchi-Ariga SM, Ariga H: DJ-1, a target protein for an endocrine disrupter, participates in the fertilization in mice. Biol Pharm Bull. 2002, 25: 853-856. 10.1248/bpb.25.853.CrossRefPubMed Okada M, Matsumoto K, Niki T, Taira T, Iguchi-Ariga SM, Ariga H: DJ-1, a target protein for an endocrine disrupter, participates in the fertilization in mice. Biol Pharm Bull. 2002, 25: 853-856. 10.1248/bpb.25.853.CrossRefPubMed
Metadaten
Titel
Functional proteomic analysis of seminal plasma proteins in men with various semen parameters
Publikationsdatum
01.12.2013
Erschienen in
Reproductive Biology and Endocrinology / Ausgabe 1/2013
Elektronische ISSN: 1477-7827
DOI
https://doi.org/10.1186/1477-7827-11-38

Weitere Artikel der Ausgabe 1/2013

Reproductive Biology and Endocrinology 1/2013 Zur Ausgabe

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.